Lower-dose contrast agent Vueway passes 3M doses
More than 3 million doses of Vueway (gadopiclenol), a lower-dose gadolinium contrast MRI agent used to diagnose and monitor conditions…
Articles by Steve Bryson, PhD
Experimental tablet calms involuntary PBA crying, laughing
Metis Biotech‘s experimental oral therapy MTS-004 was safe and eased symptoms of pseudobulbar affect (PBA), a neurological condition marked…
Protein found to be a natural brake on myelin production in the brain
Researchers have identified a protein that naturally slows myelin production — a finding that could lead to ways to repair…
Menopause doesn’t worsen multiple sclerosis disability progression
Disability progression does not seem to worsen in women with multiple sclerosis (MS) after they undergo menopause, according to…
In MS, less frequent treatment dosing schedule is equally effective
People with multiple sclerosis (MS) may receive less frequent treatments with anti-CD20 therapies without increasing their risk of disease…
Ocrevus rapidly depletes B-cells, then alters T-cells in MS patients
The CD20 inhibitor Ocrevus (ocrelizumab) rapidly depletes immune B-cells in people with multiple sclerosis (MS), as expected, but…
Vitamin D has small but significant benefits for MS patients: Study
High doses of vitamin D provide clinically modest but statistically significant benefits for adults with multiple sclerosis (MS), according to…
Genetic marker helps predict which MS therapy will work: Study
Researchers have identified a genetic biomarker that predicts whether people with relapsing forms of multiple sclerosis (MS) will respond…
Fumarate-based MS therapies have equal benefit for different races
Fumarate-based therapies like Tecfidera (dimethyl fumarate) and Vumerity (diroximel fumarate) are equally effective among Black, Hispanic, Asian, and…
Cold sore virus may play role in MS, mouse study finds
A common virus that causes cold sores, herpes simplex virus type 1 (HSV-1), may contribute to multiple sclerosis (MS).
Mesenchymal stem cell therapy shows potential: Study review
Mesenchymal stem cell (MSC) therapy is safe and well tolerated, and leads to improvements in disability and a reduction…
Neural stem cell therapy repairs myelin in MS mouse model: Study
Treatment with neural stem cells, which have the ability to differentiate into neurons and other supportive cells of the nervous…
Researchers in Sweden identify 18 new potential MS drug targets
Researchers at the Karolinska Institute in Sweden said they have identified 18 new potential protein drug targets to treat…
Hormone therapy may boost disease activity in older MS men
Older men with multiple sclerosis (MS) who use medicines that reduce the levels of androgens, or male sex hormones,…
Fat composition in ketogenic diet may influence outcomes in MS
A ketogenic diet — a very low-carbohydrate, high-fat diet — rich in long-chain, saturated fatty acids like those in butter…
Gum disease may accelerate MS progression, mouse study suggests
Gum disease caused by the bacterium Porphyromonas gingivalis (Pg) is associated with worse multiple sclerosis (MS) in a mouse…
Experimental MS therapy safely repairs myelin sheath in animals
An experimental medicine, 2-D08, boosts motor function in mice and primate models of multiple sclerosis (MS) by repairing the…
Antihistamine clemastine may worsen MS disease progression
Clemastine fumarate, an antihistamine, boosted disease progression by more than five times in adults with progressive multiple sclerosis (MS),…
Thyroid hormone FT4 may play role in development of MS
The thyroid hormone thyroxine, or FT4, may play an indirect role in the development of multiple sclerosis (MS), which…
Cleveland Clinic wins funds to compare RRMS treatment strategies
The Patient-Centered Outcomes Research Institute (PCORI) has awarded the Cleveland Clinic $6.7 million to identify optimal treatment strategies for people…
Gene variant plus mono raises MS risk: Large-scale study
The risk of multiple sclerosis (MS) is significantly higher in people who carry a variant of the HLA gene…
Tysabri infusion improves working ability for RRMS patients: Study
One year of Tysabri (natalizumab) treatment improves working ability among people with relapsing-remitting multiple sclerosis (RRMS), according to…
AAN 2025: Combined first Briumvi dose well tolerated in relapsing MS
A single 600 mg dose of Briumvi (ublituximab-xiiy) — instead of the approved 150 mg initial dose plus a…
More at-home Tysabri dosing seen for RRMS patients in France: Study
From 2019 to 2023, people with relapsing-remitting multiple sclerosis (RRMS) in France on treatment with…
Sacral neuromodulation seen to ease MS-related bladder dysfunction
Sacral neuromodulation (SNM), in which an implanted device delivers mild electrical pulses to the nerves that control the bladder, led…
Secondary contaminants from PCBs linked to higher MS risk in study
A group of manufactured chemicals called hydroxylated polychlorinated biphenyls, or OH-PCBs, which persist in the environment despite a ban on…
Brain stimulation with cognitive training fails to lower MS fatigue
A noninvasive brain stimulation technique called transcranial direct current stimulation (tDCS) doesn’t seem to ease fatigue in adults with…
Floodlight MS app cost-effective for patients to track their health: Study
The Floodlight MS app, a digital health application used to track dexterity, walking function, and cognition in people with…
MS patients highly satisfied with Sensoready autoinjector pen
Nearly all adults with relapsing forms of multiple sclerosis (MS) said they are highly satisfied with the Sensoready autoinjector…
Severe obesity in childhood linked to higher risk of MS later in life
Severe obesity during childhood and adolescence more than triples the risk of developing multiple sclerosis (MS), and…